Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis
- 12 May 2016
- journal article
- review article
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 16 (7) , 1-4
Abstract
Autoimmune myasthenia gravis (MG) is the prototypic, antibody-mediated neuromuscular disease and is characterized by a decrease in the number of functional acetylcholine receptors (AChR) within the muscle end plate zone of the neuromuscular junction (NMJ). Although the pathophysiology of AChR-mediated myasthenia gravis has been extensively studied over the last 40 years since its original description by Patrick and Lindstrom (Science 180:871–872, 1973), less is known about the much more recently described muscle-specific kinase (MuSK) antibody-mediated MG. MuSK-MG has features clinically distinct from Ach-R MG, as well as a different pattern of response to treatment and a unique immunopathogenesis.Keywords
This publication has 24 references indexed in Scilit:
- Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohortsMuscle & Nerve, 2011
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- Myasthenia gravisOrphanet Journal of Rare Diseases, 2007
- MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivoJournal of Neuroimmunology, 2005
- Successful treatment of MuSK antibody–positive myasthenia gravis with rituximabMuscle & Nerve, 2005
- Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MGNeurology, 2005
- MuSK-antibody positive myasthenia gravis: Clinical and electrodiagnostic patternsClinical Neurophysiology, 2005
- Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravisBrain, 2003
- The First American Case of Myasthenia GravisArchives of Neurology, 1988
- Autoimmune Response to Acetylcholine ReceptorScience, 1973